Summit Therapeutics PLC
Stock Chart, Company Information, and Scan Results
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Summit Therapeutics PLC Company Information, Fundamentals, and Technical Indicators
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. The company was founded in 2003 and is headquartered in Miami, Florida.
Summit Therapeutics PLC In Our Stock Scanner
As of Feb 27, 2026Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.